Data from EMC - Curated by Toby Galbraith - Last updated 18 May 2017

Licensing authority

EMA (European Medicines Agency)

Indication(s)

Eviplera is indicated for the treatment of adults infected with human immunodeficiency virus type 1 (HIV-1) without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with a viral load ≤ 100,000 HIV-1 RNA copies/mL.

Genotypic resistance testing and/or historical resistance data should guide the use of Eviplera.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Hypogonadism

Epidemiology, pathophysiology, diagnosis/treatment guidelines, recent publication summaries and more

Visit Hypogonadism


Type 2 Diabetes

View the latest epidemiology data, patient perspectives, ADA and EASD recommendations, treatment options and more

Visit Type 2 Diabetes


Related Content

More information

Category Value
Agency product number EMEA/H/C/002312
Orphan designation No
Date First Approved 28-11-2011
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder Gilead Sciences International Ltd.
Warnings

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reacti